Lunai Bioworks Inc. (RENB)
NASDAQ: RENB · Real-Time Price · USD
0.2125
-0.0100 (-4.49%)
Sep 4, 2025, 3:27 PM - Market open

Company Description

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.

It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases.

The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025.

Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Lunai Bioworks Inc.
Lunai Bioworks logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees25
CEODavid Weinstein

Contact Details

Address:
2080 Century Park East, Suite 906
Los Angeles, California 90067
United States
Phone305 918 1980
Websiterenovarogroup.com

Stock Details

Ticker SymbolRENB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001527728
CUSIP Number29350E104
ISIN NumberUS29350E1047
Employer ID45-2259340
SIC Code2834

Key Executives

NamePosition
David H. WeinsteinChief Executive Officer and Director
Nathen Fuentes CPAChief Financial Officer
Greg Duczynski Ph.D.Senior Vice President for Clinical Operations

Latest SEC Filings

DateTypeTitle
Aug 26, 20258-KCurrent Report
Aug 6, 20258-KCurrent Report
Jul 30, 2025DEF 14AOther definitive proxy statements
Jul 25, 20258-KCurrent Report
Jul 18, 2025PRE 14AOther preliminary proxy statements
Jul 14, 20258-KCurrent Report
Jul 10, 2025SCHEDULE 13D/AFiling
Jul 9, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
May 15, 202510-QQuarterly Report